Company Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids.
It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.
The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005.
Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 597 |
| CEO | Mark Foley |
Contact Details
Address: 1222 Demonbreun Street, Suite 2000 Nashville, Tennessee 37203 United States | |
| Phone | 615 724 7755 |
| Website | revance.com |
Stock Details
| Ticker Symbol | RVNC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479290 |
| CUSIP Number | 761330109 |
| ISIN Number | US7613301099 |
| Employer ID | 77-0551645 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mark J. Foley | Chief Executive Officer and Director |
| Tobin C. Schilke | Chief Financial Officer and Principal Accounting Officer |
| Jessica Serra | Head of Investor Relations and ESG |
| Jeanie D. Herbert | Senior Director of Investor Relations and Corporate Communications |
| Taryn Conway | Vice President of Marketing |
| Amie Krause | Chief People Officer |
| Dr. Conor Gallagher | Head of Medical Affairs and Aesthetics |
| Dr. David A. Hollander M.B.A., M.D. | Chief Medical Officer of Global Therapeutics Franchise Lead |
| Erica Jordan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 1, 2024 | 8-K | Current Report |
| Oct 31, 2024 | SCHEDULE 13G/A | Filing |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 18, 2024 | 8-K | Current Report |
| Oct 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |